The vaccine, based on a Phase 3 trial involving over 37,000 adults, showed effectiveness rates of 83.7% against RSV lower respiratory tract disease initially, with efficacy declining slightly after 8.6 months.
[
add
]
[
|
|
...
]
The vaccine, based on a Phase 3 trial involving over 37,000 adults, showed effectiveness rates of 83.7% against RSV lower respiratory tract disease initially, with efficacy declining slightly after 8.6 months.